NCT05250596View on ClinicalTrials.gov

COLchicine On-admission to Reduce Inflammation in Acute Coronary Syndrome (COLOR-ACS)

PHASE2CompletedINTERVENTIONAL
Enrollment

182

Participants

Timeline

Start Date

February 24, 2022

Primary Completion Date

February 24, 2024

Study Completion Date

May 30, 2024

Conditions
Non ST Segment Elevation Acute Coronary Syndrome
Interventions
DRUG

Colchicine

Colchicine 1 mg (0.5 mg for patients ≤ 70 Kg) on-admission followed by 0.5 mg/day until discharge.

DRUG

Atorvastatin

Atorvastatin 80 mg on admission followed by 80 mg/day until discharge.

Trial Locations (3)

51100

Marco Comeglio, Pistoia

59100

Gaia Chiara Selvaggia Magnaghi, Pescia

Anna Toso, Prato

All Listed Sponsors
lead

Azienda USL Toscana Centro

OTHER